Company Profile
Protara Therapeutics Stock Price, News & Analysis
- Ticker:
- TARA
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
4.10 USD (+2.50%)
Close
Last updated: August 6, 2026
244M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, TARA closed up 2.50% at $4.10. No new same-company headline was identified in the current news window.
Company overview
Immunopotentiator Company
Protara Therapeutics develops TARA-002, a cell-based immunopotentiator derived from the same bacterial strain used in a historically approved immunotherapy.
Lymphatic Malformations
The STARBORN program evaluates intralesional TARA-002 in pediatric and adult lymphatic malformations.
Bladder Cancer
The ADVANCED program evaluates intravesical TARA-002 in high-grade non-muscle invasive bladder cancer across BCG-unresponsive and BCG-naïve populations.
Future catalysts
Protara expects to complete enrollment in the BCG-unresponsive registrational cohort of ADVANCED-2 in the second half of 2026.
The registrational ADVANCED-3 study in BCG-naïve patients is expected to begin in the second half of 2026.
A BLA submission for TARA-002 in lymphatic malformations is planned for the second half of 2027.
Recent news
- 01
Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA
Source: Protara Therapeutics
- 02
- 03
- 04
Protara Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update
Source: Protara Therapeutics
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Protara Therapeutics (TARA)?
Protara Therapeutics (TARA) most recently closed at 4.10 USD, a +2.50% move versus the previous session.
What is the market cap of Protara Therapeutics (TARA)?
Protara Therapeutics currently has a market capitalization of 244M USD on BioPharmSignal.
What does Protara Therapeutics do?
Immunopotentiator Company Protara Therapeutics develops TARA-002, a cell-based immunopotentiator derived from the same bacterial strain used in a historically approved immunotherapy. Lymphatic Malformations The STARBORN program evaluates intralesional TARA-002 in pediatric and adult lymphatic malformations. Bladder Cancer The ADVANCED program evaluates...
On which exchange is TARA stock listed?
Protara Therapeutics (TARA) is associated with NASDAQ, United States, Biopharma.
What is TARA-002?
A BLA submission for TARA-002 in lymphatic malformations is planned for the second half of 2027.
Which conditions is Protara Therapeutics targeting with TARA-002?
Protara Therapeutics is associated with cancer therapeutics based on its company overview and current catalyst commentary.
How does Protara Therapeutics describe recent progress with TARA-002?
A BLA submission for TARA-002 in lymphatic malformations is planned for the second half of 2027.
What is ADVANCED-2?
Protara expects to complete enrollment in the BCG-unresponsive registrational cohort of ADVANCED-2 in the second half of 2026.